PCI-32765 is an orally active, small molecule inhibitor of Bruton’s tyrosine kinase (Btk), an essential element of the B-cell antigen receptor (BCR) signaling pathway that causes tumor expansion.
The drug candidate is being evaluated under Phase 1 and 2 studies in B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.
As per the deal, both the companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities.
Janssen has made an upfront payment of $150m and will make additional payments based upon the achievement of certain development and regulatory milestones.